All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F10%3A00002429" target="_blank" >RIV/00023001:_____/10:00002429 - isvavai.cz</a>

  • Result on the web

    <a href="http://dx.doi.org/10.1038/ki.2009.506" target="_blank" >http://dx.doi.org/10.1038/ki.2009.506</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1038/ki.2009.506" target="_blank" >10.1038/ki.2009.506</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial

  • Original language description

    The cost of immunosuppression following transplantation can be reduced by using generic ciclosporin (for example, Equoral) rather than innovator ciclosporin drugs such as Neoral. Thus, this study aims to evaluate the interchangeability, safety, and tolerability of Equoral, a generic ciclosporin, with Neoral in stable adult renal transplant recipients. This was a multicenter, randomized, open-label, parallel-group clinical trial in stable renal transplant patients, comparing 6 months of treatment with Equoral with the same treatment period on Neoral. The primary end point was the between-treatment comparison of the total daily ciclosporin dose at the end of the study. A total of 99 patients were enrolled and constituted the full analysis/safety population, and 78 patients forming the per-protocol population were assessed for efficacy. Equoral was found to be equivalent to Neoral with regard to the primary end point of daily dose at the end of the study. This was supported by comparable

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FJ - Surgery including transplantology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2010

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Kidney International

  • ISSN

    0085-2538

  • e-ISSN

  • Volume of the periodical

    77

  • Issue of the periodical within the volume

    suppl. 115

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    5

  • Pages from-to

    "S12"-"S16"

  • UT code for WoS article

    000274445800003

  • EID of the result in the Scopus database